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Src is a nonreceptor tyrosine kinase that coordinates
responses to diverse soluble and adhesive signaling
molecules and regulates cell proliferation, survival, differen-
tiation and migration [1]. Normally, Src activity is tightly
regulated, and Src-catalyzed phosphorylation is counterbal-
anced by phosphotyrosine phosphatases [2, 3]. However,
deregulated mutant Src causes malignant transformation
when highly expressed [4]. Src transformation is dose
dependent, but it has been unclear how much mutant Src,
compared with endogenous Src, is required for transforma-
tion [5]. Here, we show that transformation requires high-
level overexpression of mutant src mRNA, in part because
active Src protein is degraded by ubiquitin-mediated prote-
olysis [6]. We show that active but not inactive Src protein
is downregulated depending on the putative tumor
suppressor and E3 ubiquitin ligase component, Cullin-5
(Cul5). Cul5 removal synergizes with physiological levels
of mutant src mRNA to increase protein tyrosine phosphor-
ylation, induce morphological transformation, and deregu-
late growth. Cul5 also represses Src-induced tumorigenesis
and regulates Src signaling in normal cells. These results
suggest that, when Src is activated by mutation or physio-
logical mechanisms, its effects are limited by Cul5,
which downregulates active Src and its phosphorylated
substrates. These findings demonstrate the importance of
a new mechanism that downregulates Src signaling in cells.
Results and Discussion
We generated fibroblast cell lines in which wild-type or mutant
mouse src genes were expressed at various levels. The
mutants encode proteins SrcY529F (SrcYF), which lacks its
C-terminal inhibitory Y529 and is fully active [7], and
SrcQ530* (SrcQ*), which is partially phosphorylated at Y529
because of truncation of six C-terminal amino acids and is
partly active [8]. SrcQ* also escapes regulation by PDZ-domain
proteins binding to the Src C terminus [9]. To facilitate
measurement of expression levels, we transduced the src
genes into src2/2 mouse embryo fibroblasts (MEFs) [10],
immortalized by the 3T3 protocol [11], and the expression
levels of ectopic src mRNA and Src protein were compared
to the endogenous levels in src+/+ 3T3 MEFs. We define
‘‘normal’’ src mRNA or Src protein level as being equal to
that in src+/+ MEFs and thus corresponds to expression from
both genomic alleles.
*Correspondence: jcooper@fhcrc.orgWe isolated polyclonal src2/2 MEF cell lines with different
expression levels of control SrcWT and activated SrcYF and
SrcQ*. Lines with 50%–100% of the normal level of src mRNA
were designated WT= , YF=, and Q*= , whereas lines WT>,
YF>, and Q*> overexpressed src mRNA 20-, 7-, and 9-fold,
respectively (Figure 1A and Figure S1 available online). Over-
expressed mutants but not wild-type src caused extensive
tyrosine phosphorylation of a wide range of cellular proteins,
but had little effect when expressed at normal level (Figure S2).
Overexpressed mutants but not wild-type src also deregulated
cell growth in monolayer and semisolid media cultures
(Figures 1B and 1C and Figure S3). However, cell lines YF=
and Q*=, expressing mutant src at normal RNA level, were
not transformed (Figures 1B and 1C and Figure S3), suggest-
ing that src must be overexpressed as well as mutationally
activated for transformation.
Active Src protein is downregulated by the proteasome [6], so
mutant Src protein may be underexpressed even though its
mRNA level is normal. We measured Src protein levels by using
western blotting. Wild-type or mutant Src, overexpressed 7- to
20-fold as mRNA, was overexpressed 15- to 30-fold as protein
(Figure 1D and Figure S4). However, mutant YF or Q* Src
protein, expressed at normal mRNA level, was <20% as abun-
dant as the wild-type control (Figures 1D and 1E). This suggests
that negative feedback by proteolysis might limit expression of,
and transformation by, mutant Src and that the feedback mech-
anism may be overwhelmed when Src is overexpressed.
To investigate the importance of proteolysis in Src expres-
sion and transformation, we inhibited expression of selected
ubiquitin E3 ligases that may target active Src or its substrates.
We used retroviral small hairpin RNA (shRNA) to inhibit expres-
sion of either the ubiquitin E3 ligase Cbl or the E3 ligase
component Cul5, both previously implicated in degradation
of active SFKs [12–15] or Src substrates [15]. The latter forms
complexes with elongin B/C, Rbx2, and one of the suppres-
sors of cytokine signaling (SOCS) proteins [16–18]. There are
more than 20 SOCS proteins, of which seven contain an Src
homology-2 (SH2) domain that allows them to bind to phos-
photyrosine proteins [19], possibly including active Src.
Knockdown of Cul5 but not Cbl greatly enhanced mutant-
Src-protein expression to nearly the normal level (Figures 2B
and 2C and Figure S5), but had no effect on wild-type Src
(Figures 2A and 2C). As a control, knockdown of Cullin-2
(Cul2) had no effect (data not shown). Importantly, knockdown
of Cul5 did not increase src mRNA levels (Figure 2D). These
results indicate that Cul5 regulates the level of activated
mutant Src protein but not mRNA and does not affect inactive
Src protein.
Cul5 also regulated the level of active wild-type Src. The
absence of Csk from csk2/2 cells activates endogenous Src
[20], which is rescued by re-expressing active Csk but not
inactive CskR222 [21]. We found that removing Cul5, but not
Cbl, increased the level of active Src in csk2/2 or CskR222
cells, but did not affect the level of inactive Src in csk2/2 cells
re-expressing functional Csk (Figure 2E and Figure S6). This
suggests that Cul5 is the main E3 ligase that downregulates
wild-type Src if it is activated by absence of Csk. Furthermore,
we found that removing Cul5 enhanced both basal and
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results show that Cul5 downregulates active endogenous Src
protein.
Figure 1. Activated Mutant Src Expressed at
Normal mRNA Level Does Not Transform and Is
Underrepresented at the Protein Level
(A) src mRNA levels compared with gapdh
control mRNA levels by RT-PCR.
(B) Photomicrographs of confluent cultures
showing loss of contact inhibition in YF> and
Q*> lines but not YF= , Q*= , WT=, or WT> .
(C) Colony number after growth in soft agar
shown as the mean6 SD from three independent
samples per cell line, representative of two inde-
pendent assays. In this and subsequent figures,
*p < 0.05; **p < 0.01; ***p < 0.001.
(D) Western-blot analysis of Src protein levels
relative to MAPK loading control.
(E) Relative level of Src protein estimated by titra-
tion of extract protein and western blot analysis.
Densitometry of repeat experiments showed that
Src levels in WT= , YF=, and Q*= lines were in the
ratio of 1.00, 0.20, and 0.25.
Consistent with the increased levels of
activated mutant Src, we found that
removing Cul5 induced partial transfor-
mation of YF= cells (Figure 3). Removing
Cul5 but not Cbl or Cul2 relieved contact
inhibition (Figure 3A), induced morpho-
logical transformation and subcellular
redistribution of the Src substrate and
focal adhesion protein paxillin (Fig-
ure 3B), enhanced tyrosine phosphory-
lation of cellular substrates (Figure S7B),
and inhibited cell spreading on tissue culture plastic
(Figure 3C). Also, removing Cul5 stimulated the anchorage-
independent growth of YF = cells (Figure 3D and Figure S7).Figure 2. Removal of Cul5 Increases the Levels
of Activated Src Protein but Not mRNA
(A and B) WT= , and YF= cell lines were infected
with shRNAs targeting the ubiquitin E3 ligases
Cul5 or Cbl and analyzed in triplicate by western
blotting. Cul50 shRNA targets a different
sequence in cul5 mRNA.
(C) Blots from (A) and (B) and Figure S5 were
analyzed with densitometry and shown as the
mean 6 SD of the ratio of Src to MAPK loading
control.
(D) Cul5 shRNA knockdown in either WT= or YF=
cells does not increase src mRNA level. Mean 6
SD of the ratio of src mRNA to arbp mRNA level,
measured by qPCR, with the ratio for WT= with
vector cells set to 1.00. Values are from RNA puri-
fied from three independent experiments, each
assayed in triplicate.
(E) csk2/2 cells re-expressing Csk, empty vector,
or CskR222 were infected with shRNAs targeting
the ubiquitin E3 ligases Cul5 or Cbl and analyzed
by western blotting (see Figure S6). Data are
plotted as the mean 6 SD of the ratio of Src to
MAPK protein, normalized to vector control for
each cell line.
(F) Western analysis of lysates from serum-
deprived WT= cells 6 Cul5 shRNA in suspension
(S) or plated on fibronectin (FN) for the indicated
time (hr).
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159Figure 3. Removal of Cul5 from Cells Expressing Normal Level of Activated src mRNA Induces Transformation
(A) Saturation density of YF= cells infected with Cul5, Cul2, or Cbl shRNAs.
(B) Fluorescence micrographs showing cell morphology and localization of paxillin (green), filamentous actin (red), and DNA (blue) in YF= cells with either
vector or Cul5 shRNA.
(C) Photomicrographs of cells 0.5 or 4 hr after plating on fibronectin. Arrowheads indicate spreading cells.
(D) Soft-agar-colony assay. Anchorage-independent growth of WT= or YF= cells expressing either vector or shCul5.
(E) Soft-agar-colony formation by Cul5 shRNA-infected csk2/2 cells expressed as a ratio to the corresponding control.
(F) K-rasG12D; E1A or p532/2; E1A MEFs infected with either vector or Cul50 shRNA were assayed for anchorage-independent growth. All data are
representative of at least two independent assays and data represented in (A) and (D)–(F) are the mean6 SD from three independent samples per cell line.Removing Cul5 had no detectable effects on WT= cells
(Figure 3D and Figure S7; data not shown), or on csk2/2 cells
in which Csk was re-expressed, but increased the transforma-
tion of csk2/2 cells or csk2/2 cells expressing inactive
CskR222 (Figure 3E). However, Cul5 removal had no effect
on Src protein levels (Figure S8A), tyrosine phosphorylation
of cellular substrates (Figure S8B), or transformation of cells
(Figure 3F) that were partially transformed either by oncogenic
K-RasG12D and adenovirus E1A or by p53 deletion and E1A [22,
23]. These results indicate that Cul5 removal specifically stim-
ulates transformation by Src that is activated by mutation or byabsence of Csk but has little effect on cells transformed by E1A
and cooperating oncogenes.
We tested the effect of Cul5 on Src-induced tumors, using
xenograft assays in nude mice (Figures 4A–4E). Removal of
Cul5 from cells with wild-type Src induced tumors, but only
after long latency (median 60 days, Figure 4A). Mutant Src at
a normal RNA level was also weakly tumorigenic (median
latency 38 days), but the combination of Cul5 removal with
mutant Src significantly increased incidence and decreased
latency (median 20 days; p < 0.05 relative to either mutant
Src alone or Cul5 knockdown alone). Tumors were readily
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160detected with ultrasound or visually (Figures 4B and 4C). The
increase in tumor volume over time showed a trend that re-
flected tumor latency (Figure 4D). Tumors were also induced
by highly overexpressed mutant Src, and these tumors were
highly vascularized hemangiosarcomas (Figure 4E, top
panels), as expected [24, 25]. However, tumors induced by
low levels of mutant Src, with or without Cul5 knockdown,
were less vascular fibrosarcomas or rhabdomysarcomas.
Therefore, expression of mutant src mRNA at endogenous
level synergizes with Cul5 removal for tumor induction, and
these tumors are qualitatively different from those induced
by high levels of mutant Src. This suggests that Cul5 may
oppose specific Src-dependent signaling pathways.
We wondered whether Cul5 opposes Src transformation
solely by downregulating Src or whether it may also destabilize








Figure 4. Cul5 Suppresses Tumorigenesis by
Active src
(A–E) Nu/nu mice were injected in both flanks with
indicated cell lines and monitored for tumors. (A)
shows a Kaplan-Meier graph of initial tumor
appearance on each flank from a total of 14–16
flanks. Statistical significance is based on the log-
rank test. (B) shows an ultrasound and (C) shows
a photograph of nu/nu mice injected with indi-
cated cells 12 days after injection. (D) shows
quantification of tumor volumes, mean 6 SE
from 7–8 mice injected with indicated cell line.
All differences are significant at p < 0.05 (Kol-
gorov-Smirnov test). (E) shows hematoxylin and
eosin staining of formalin-fixed tumor sections.
Left panels show tumor borders. Right panels
shows the tumor interior. Asterisks indicate
normal/tumor tissue boundary, with normal tissue
on the left.
(F) Dok1 or MAPK loading control from WT= and
YF= cell lines with and without removal of Cul5.
(G) Ratio of Dok1 protein to MAPK protein in WT=
and YF= cell lines with and without removal of
Cul5, with WT= + vector ratio arbitrarily set to
1.00. Data shown represent mean 6 SE from five
immunoblots, each using unique cell lysates.
(H) Model. Cul5 opposes Src transformation by
targeting active Src and phosphorylated
substrates for degradation.
have been identified as targets of
SOCS-Cul5 complexes [15, 17, 26]. We
reasoned that, if Cul5 destabilizes Src
alone, then expressing mutant Src at
normal protein level should induce
transformation, even if Cul5 is present.
To test this, we made clones of cells
with different levels of Src expression.
As shown in Figures S9A–S9C, overex-
pression of mutant src mRNA approxi-
mately 3-fold allowed mutant Src
protein to be made at near-normal level
(clones YF16 and Q*10), but there was
little change in protein tyrosine phos-
phorylation (Figure S9D) and the cells
were not transformed (Figure S9E).
Approximately eight-fold overexpres-
sion of mutant Src protein allowed
partial transformation (clones YF6 and
Q*9, Figure S9). Therefore, transformation caused by removal
of Cul5 from cells with endogenous levels of mutant src mRNA
is not simply due to the increased level of mutant Src protein.
Cul5 must have other effects important for transformation by
active Src but not by other oncogenes like E1A (Figure 3F).
Because Cul5 complexes with certain SOCS proteins can
recognize tyrosine-phosphorylated targets [19], it seems likely
that Cul5 also downregulates phosphorylated Src substrates.
Consistent with this concept, a preliminary phosphoproteo-
mics screen suggested that levels of the Src substrate Dok1,
a cytoplasmic protein implicated in negative regulation of
Src [27, 28], may be increased when Cul5 is removed from cells
expressing low levels of activated Src (Supplemental Experi-
mental Procedures). Indeed, western blotting showed an
increase in Dok1-protein level in YF= cells lacking Cul5
(Figures 4F and 4G). When Dok1-protein levels were adjusted
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161for Src-induced increase in dok1 mRNA, it appears that active
Src causes a decrease in Dok1 protein and that this decrease
requires Cul5 (Figures S10A and S10B). Although the relevance
of Dok1 for Src-mediated transformation is unknown, Dok1 is
a candidate for a Src substrate that may be targeted for degra-
dation by Cul5.
Taken together, these results suggest that Cul5 opposes
Src transformation by downregulating both active Src and
proteins it has phosphorylated (Figure 4H). Cul5 is presumably
acting in a complex with one or more SOCS proteins that
contain SH2 domains through which they bind to tyrosine-
phosphorylated substrates. There are seven such SOCS
proteins [19], and we have detected at least two (SOCS1 and
SOCS3) in the cells studied here, so there may be functional
redundancy. Interestingly, however, many SOCS proteins are
induced by mitogens or transformation [17], in some cases
via Src [29, 30]. This suggests a negative-feedback loop in
which Src activity stimulates expression of SOCS proteins,
which then bind to active Src and its substrates and target
them for ubiquitination by Cul5 and subsequent degradation.
This mechanism may have evolved to fine-tune Src activity in
response to physiological stimuli.
The weak oncogenic activity of mutant src resembles that of
H-ras-1, which is infrequently mutated in human cancers and
only causes frank transformation when overexpressed [31–
33], and contrasts with K-ras, which is commonly mutated in
human cancers and causes malignancy in animals without
overexpression [22, 33]. Consistent with this, src is commonly
overexpressed but only very infrequently mutated in human
cancers [8, 34–36]. One possibility is that mutant src would
require a cooperating genetic change, such as loss of cul5.
The cul5 gene maps to a region (11q22-23) that undergoes
loss of heterozygosity (LOH) in many cancers [37]. cul5 mRNA
is underexpressed in a substantial fraction of poor-prognosis
breast cancers and neuroblastomas [38, 39], and Cul5 overex-
pression inhibits estrogen-dependent and -independent
growth of the breast-cancer cell line T47D [40]. Thus, Cul5
may be a tumor suppressor, and its suppressive effects may
be in part due to its ability to inhibit Src.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and
ten figures and can be found with this article online at http://
www.current-biology.com/supplemental/S0960-9822(08)01628-X.
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